Cargando…
Migraine Prevention with Erenumab: Focus on Patient Selection, Perspectives and Outcomes
Erenumab is a monoclonal antibody targeting the calcitonin gene-related peptide (CGRP) receptor suitable for episodic and chronic migraine prevention. Randomized clinical trials proved the superiority of erenumab to placebo in a strictly selected population, while real-world studies confirmed treatm...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8994624/ https://www.ncbi.nlm.nih.gov/pubmed/35411146 http://dx.doi.org/10.2147/TCRM.S263825 |